Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma

被引：0
|
作者：
Romaguera, Jorge [1 ]
Fayad, Luis [1 ]
McLaughlin, Peter [1 ]
Pro, Barbara [1 ]
Rodriguez, Maria Alma [1 ]
Wang, Michael [1 ]
Weaver, Pamela [1 ]
Hartig, Kimberly [1 ]
Kwak, Larry [1 ]
Feldman, Tatyana [2 ]
Smith, Judy [2 ]
Ford, Peggy [2 ]
Goldberg, Stuart [2 ]
Pecora, Andrew [2 ]
Goy, Andre [2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Div Canc Med, Houston, TX 77030 USA
[2] Hackensack Univ, Med Ctr, Dept Lymphoma, Hackensack, NJ USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1049 / 1049
页数：1
相关论文
共 50 条
  • [41] Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Report on An Ongoing Phase I/II Trial
    Hess, Georg
    Keller, Ulrich
    Atta, Johannes
    Buske, Christian
    Borchmann, Peter
    Medler, Christoph
    Witzens-Harig, Mathias
    Dreyling, Martin H.
    BLOOD, 2011, 118 (21) : 1159 - 1159
  • [42] Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Report on an Ongoing Phase I/II Trial
    Hess, Georg
    Keller, Ulrich
    Atta, Johannes
    Bitz, Ulrich
    Lerchenmueller, Christian
    Karola, Wagner
    Medler, Christoph
    Ruckes, Christian
    Witzens-Harig, Mathias
    Huebel, Kai
    LaRosee, Paul
    Dreyling, Martin H.
    BLOOD, 2015, 126 (23)
  • [43] Rituximab, Lenalidomide, and Bortezomib in the First-Line or Second-Line Treatment of Patients with Mantle Cell Lymphoma a Phase I/II Trial
    Flinn, Ian W.
    Mainwaring, Mark
    Peacock, Nancy
    Shipley, Dianna
    Arrowsmith, Edward
    Savona, Michael R.
    Hainsworth, John D.
    Berdeja, Jesus G.
    BLOOD, 2012, 120 (21)
  • [44] Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma
    Inwards, D. J.
    Fishkin, P. A.
    LaPlant, B. R.
    Drake, M. T.
    Kurtin, P. J.
    Nikcevich, D. A.
    Wender, D. B.
    Lair, B. S.
    Witzig, T. E.
    ANNALS OF ONCOLOGY, 2014, 25 (10) : 2020 - 2024
  • [45] Phase I Trial of Rituximab, Cladribine and Temsirolimus (RCT) for Initial Therapy of Mantle Cell Lymphoma
    Inwards, David J.
    Fishkin, Paul
    LaPlant, Betsy R.
    Drake, Matthew T.
    Kurtin, Paul
    Nikcevich, Daniel
    Wender, Donald
    Lair, Bradley
    Witzig, Thomas E.
    BLOOD, 2012, 120 (21)
  • [46] Preliminary results of a phase I/II study of weekly or twice weekly bortezomib in combination with rituximab, in patients with follicular lymphoma, mantle cell lymphoma and Waldenstrom's macroglobulinaemia
    Agathocleous, A.
    Rule, S.
    Johnson, P.
    Radford, J. A.
    Lafon, N.
    Hunter, H.
    Kerr, J. P.
    Neeson, S. M.
    Matthews, J.
    Strauss, S.
    Montoto, S.
    Rohatiner, A. Z. S.
    Lister, T. A.
    BLOOD, 2007, 110 (11) : 754A - 754A
  • [47] A Phase II Trial of Combination Bortezomib (Velcade®) and Rituximab for Untreated "High Tumor Burden" Indolent Non-Hodgkin Lymphoma (NHL).
    David, Kevin A.
    Smith, Mitchell R.
    Lossos, Izidore S.
    Roubal, Eren
    Winter, Jane N.
    Rosen, Steve T.
    Gordon, Leo I.
    Evens, Andrew M.
    BLOOD, 2008, 112 (11) : 699 - 699
  • [48] The Final Results of a Phase I Study Using Bortezomib (Velcade), Cladribine, and Rituximab (VCR) in Treating Mantle Cell Lymphoma
    Pu, Jeffrey J.
    Berger, Kristin
    Zheng, Chunlei
    Do, Nhan V.
    Claxton, David F.
    Ehmann, W. Christopher
    Drabick, Joseph J.
    Thomas, Loughran P., Jr.
    Epner, Elliot
    BLOOD, 2023, 142
  • [49] Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
    Bega, Giulia
    Olivieri, Jacopo
    Riva, Marcello
    Scapinello, Greta
    Paolini, Rossella
    Finotto, Silvia
    Sartori, Roberto
    Lucchini, Elisa
    Guandalini, Gianmarco
    Facchinelli, Davide
    Tisi, Maria Chiara
    Basso, Marco
    Ballotta, Laura
    Piazza, Francesco
    Ferrarini, Isacco
    Visco, Carlo
    CANCERS, 2021, 13 (23)
  • [50] Bortezomib plus DA-EPOCH-rituximab followed by bortezomib maintenance versus observation in previously untreated mantle cell lymphoma (MCL)
    Grant, C.
    Dunleavy, K.
    Tweito, M.
    Steinberg, S. M.
    Pittaluga, S.
    Jaffe, E. S.
    Wiestner, A.
    Wilson, W. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345